TY - JOUR
T1 - Identification of coagulation factor XI as a ligand for platelet apolipoprotein e receptor 2 (ApoER2)
AU - White-Adams, Tara C.
AU - Berny, Michelle A.
AU - Tucker, Erik I.
AU - Gertz, Jacqueline M.
AU - Gailani, David
AU - Urbanus, Rolf T.
AU - De Groot, Philip G.
AU - Gruber, András
AU - McCarty, Owen J.T.
PY - 2009/10
Y1 - 2009/10
N2 - OBJECTIVE-: Factor XI (FXI) promotes hemostasis and thrombosis through enhancement of thrombin generation and has been shown to play a critical role in the formation of occlusive thrombi in arterial injury models. The aim of this study was to investigate the mechanisms governing interactions between FXI and platelets. METHODS AND RESULTS-: Platelet adhesion to immobilized FXI was abrogated in the presence of the low-density lipoprotein (LDL) receptor antagonist, receptor-associated protein (RAP), soluble recombinant apolipoprotein E receptor 2 (ApoER2), or the LDL-binding domain 1 or 2 of ApoER2. FXI supported wild-type murine platelet binding; in contrast, ApoER2-deficient murine platelets did not adhere to FXI. In the presence of shear, platelet aggregates formed on FXI or activated FXI (FXIa) surfaces, whereas the presence of RAP, binding domain 1 of ApoER2, or an anti-GPIbα mAb blocked platelet adhesion to FXI or FXIa under shear. Soluble FXI bound to immobilized ApoER2′ with an affinity of 61 nmol/L. CONCLUSIONS-: This study has identified apolipoprotein E receptor 2 (ApoER2, LRP8), a member of the LDL receptor family, as a platelet receptor for FXI. The interaction of FXI with other cell types that express ApoER2 remains to be explored.
AB - OBJECTIVE-: Factor XI (FXI) promotes hemostasis and thrombosis through enhancement of thrombin generation and has been shown to play a critical role in the formation of occlusive thrombi in arterial injury models. The aim of this study was to investigate the mechanisms governing interactions between FXI and platelets. METHODS AND RESULTS-: Platelet adhesion to immobilized FXI was abrogated in the presence of the low-density lipoprotein (LDL) receptor antagonist, receptor-associated protein (RAP), soluble recombinant apolipoprotein E receptor 2 (ApoER2), or the LDL-binding domain 1 or 2 of ApoER2. FXI supported wild-type murine platelet binding; in contrast, ApoER2-deficient murine platelets did not adhere to FXI. In the presence of shear, platelet aggregates formed on FXI or activated FXI (FXIa) surfaces, whereas the presence of RAP, binding domain 1 of ApoER2, or an anti-GPIbα mAb blocked platelet adhesion to FXI or FXIa under shear. Soluble FXI bound to immobilized ApoER2′ with an affinity of 61 nmol/L. CONCLUSIONS-: This study has identified apolipoprotein E receptor 2 (ApoER2, LRP8), a member of the LDL receptor family, as a platelet receptor for FXI. The interaction of FXI with other cell types that express ApoER2 remains to be explored.
KW - Apolipoprotein E receptor 2
KW - Factor XI
KW - GPIb
KW - LRP8
KW - Platelets
UR - http://www.scopus.com/inward/record.url?scp=70349569047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349569047&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.109.187393
DO - 10.1161/ATVBAHA.109.187393
M3 - Article
C2 - 19661487
AN - SCOPUS:70349569047
SN - 1079-5642
VL - 29
SP - 1602
EP - 1607
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 10
ER -